NeuroStat Pharmaceuticals

NeuroStat Pharmaceuticals is a clinical-stage biotechnology company focused on the development of neuroprotective therapies for traumatic brain injury (TBI). As a subsidiary of Abliva AB (formerly NeuroVive Pharmaceutical), the company is primarily dedicated to advancing its lead candidate, NeuroStat, a specialized formulation of cyclosporine. The therapy works by inhibiting the mitochondrial permeability transition pore (mPTP) to prevent mitochondrial dysfunction and secondary brain damage following head trauma. NeuroStat has received Orphan Drug Designation from both the FDA and the EMA, highlighting its potential to address significant unmet needs in acute neurological care. The company's clinical efforts have included the Phase 2 CHIC study, positioning the asset for further pivotal development through strategic partnerships.